Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vγ9Vδ2 T-cell killing

被引:6
|
作者
Wu, Zeguang [1 ]
Lamao, Qiezhong [1 ]
Gu, Meichao [1 ]
Jin, Xuanxuan [1 ]
Liu, Ying [1 ]
Tian, Feng [1 ]
Yu, Ying [1 ]
Yuan, Pengfei [2 ]
Gao, Shuaixin [3 ]
Fulford, Thomas S. [4 ]
Uldrich, Adam P. [4 ,5 ]
Wong, Catherine C. L. [6 ]
Wei, Wensheng [1 ]
机构
[1] Peking Univ, Genome Editing Res Ctr,State Key Lab Prot & Plant, Biomed Pioneering Innovat Ctr,Sch Life Sci, Beijing Adv Innovat Ctr Genom,Peking Tsinghua Ctr, Beijing 100871, Peoples R China
[2] EdiGene Inc, Life Sci Pk, Beijing 102206, Peoples R China
[3] Peking Univ, Hlth Sci Ctr, Ctr Precis Med Multi Res, Beijing 100191, Peoples R China
[4] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Parkville, Vic 3010, Australia
[5] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia
[6] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Med Res Ctr,Clin Res Inst,Peking Tsinghua Ctr, Beijing 100871, Peoples R China
基金
中国国家自然科学基金;
关键词
Butyrophilin; V gamma 9V delta 2 T-cell; Cancer-specific immune evasion; Glutaminyl-peptide cyclotransferase-like; Pyrophosphate metabolite; Immunotherapy; PHOSPHORYLATED ANTIGENS; ACTIVATION; GENES; BTN3A1; STIMULATION; RFX; TCR;
D O I
10.1038/s41423-024-01135-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
V gamma 9V delta 2 T cells are specialized effector cells that have gained prominence as immunotherapy agents due to their ability to target and kill cells with altered pyrophosphate metabolites. In our effort to understand how cancer cells evade the cell-killing activity of V gamma 9V delta 2 T cells, we performed a comprehensive genome-scale CRISPR screening of cancer cells. We found that four molecules belonging to the butyrophilin (BTN) family, specifically BTN2A1, BTN3A1, BTN3A2, and BTN3A3, are critically important and play unique, nonoverlapping roles in facilitating the destruction of cancer cells by primary V gamma 9V delta 2 T cells. The coordinated function of these BTN molecules was driven by synchronized gene expression, which was regulated by IFN-gamma signaling and the RFX complex. Additionally, an enzyme called QPCTL was shown to play a key role in modifying the N-terminal glutamine of these BTN proteins and was found to be a crucial factor in V gamma 9V delta 2 T cell killing of cancer cells. Through our research, we offer a detailed overview of the functional genomic mechanisms that underlie how cancer cells escape V gamma 9V delta 2 T cells. Moreover, our findings shed light on the importance of the harmonized expression and function of gene family members in modulating T-cell activity.
引用
收藏
页码:362 / 373
页数:12
相关论文
共 50 条
  • [1] Butyrophilin3A proteins and Vγ9Vδ2 T cell activation
    Gu, Siyi
    Borowska, Marta T.
    Boughter, Christopher T.
    Adams, Erin J.
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2018, 84 : 65 - 74
  • [2] Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody
    de Bruin, Renee C. G.
    Stam, Anita G. M.
    Vangone, Anna
    Henegouwen, Paul M. P. van Bergen en
    Verheul, Henk M. W.
    Sebestyen, Zsolt
    Kuball, Jurgen
    Bonvin, Alexandre M. J. J.
    de Gruijl, Tanja D.
    van der Vliet, Hans J.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01) : 308 - 317
  • [3] The PPARα pathway in Vγ9Vδ2 T cell anergy
    Poupot, Mary
    Boissard, Frederic
    Betous, Delphine
    Bardouillet, Laure
    Fruchon, Severine
    L'Faqihi-Olive, Fatima
    Pont, Frederic
    Mekaouche, Mourad
    Ingoure, Sophie
    Sicard, Helene
    Dubreuilh, Guy
    Fournie, Jean-Jacques
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2014, 19 (04) : 649 - 658
  • [4] The PPARα pathway in Vγ9Vδ2 T cell anergy
    Mary Poupot
    Frédéric Boissard
    Delphine Betous
    Laure Bardouillet
    Séverine Fruchon
    Fatima L’Faqihi-Olive
    Frédéric Pont
    Mourad Mekaouche
    Sophie Ingoure
    Hélène Sicard
    Guy Dubreuilh
    Jean-Jacques Fournié
    Cellular & Molecular Biology Letters, 2014, 19 : 649 - 658
  • [5] Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
    Giannotta, Claudia
    Autino, Federica
    Massaia, Massimo
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [6] Improving the Efficiency of Vγ9Vδ2 T Cell Immunotherapy in Cancer
    Hoeres, Timm
    Smetak, Manfred
    Pretscher, Dominik
    Wilhelm, Martin
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [7] Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens
    Moulin, Morgane
    Alguacil, Javier
    Gu, Siyi
    Mehtougui, Asmaa
    Adams, Erin J.
    Peyrottes, Suzanne
    Champagne, Eric
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2017, 74 (23) : 4353 - 4367
  • [8] RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor
    Sebestyen, Zsolt
    Scheper, Wouter
    Vyborova, Anna
    Gu, Siyi
    Rychnavska, Zuzana
    Schiffler, Marleen
    Cleven, Astrid
    Cheneau, Coraline
    van Noorden, Martje
    Peigne, Cassie-Marie
    Olive, Daniel
    Lebbink, Robert Jan
    Oostvogels, Rimke
    Mutis, Tuna
    Schuurhuis, Gerrit Jan
    Adams, Erin J.
    Scotet, Emmanuel
    Kuball, Jurgen
    CELL REPORTS, 2016, 15 (09): : 1973 - 1985
  • [9] Phosphoantigen recognition by Vγ9Vδ2 T cells
    Herrmann, Thomas
    Karunakaran, Mohindar Murugesh
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 (11)
  • [10] Specific Requirements for Vγ9Vδ2 T Cell Stimulation by a Natural Adenylated Phosphoantigen
    Vantourout, Pierre
    Mookerjee-Basu, Jayati
    Rolland, Corinne
    Pont, Frederic
    Martin, Helene
    Davrinche, Christian
    Martinez, Laurent O.
    Perret, Bertrand
    Collet, Xavier
    Perigaud, Christian
    Peyrottes, Suzanne
    Champagne, Eric
    JOURNAL OF IMMUNOLOGY, 2009, 183 (06) : 3848 - 3857